The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications.

Compared to beta-3 agonists, the continuous use of oxybutynin is associated with a significantly increased risk of fall/fracture, and newer OAB anticholinergics are associated with a significantly increased risk of delirium.